Selected Clinical Features of Relapse APL Cases
| Case No. . | Age/Sex . | PB . | FAB Class . | Cytogenetics . | ||
|---|---|---|---|---|---|---|
| WBC (109/L) . | Bl + Pros (%) . | t(15;17) Marker . | Other Marker . | |||
| 1 | 63/M | 13.1 | 42 | M3 | + | +8 |
| 2 | 20/M | 7.3 | 66 | M3 | + | − |
| 3 | 68/M | 0.7 | 13 | M3 | + | − |
| 4 | 27/F | 55.2 | 80 | M3v | + | − |
| 5 | 47/M | 2.4 | 42 | M3 | + | del(16)(q11q24) |
| 6 | 29/F | 68.6 | 85 | M3 | + | − |
| 7 | 25/F | 76.0 | 32 | M3v | + | − |
| 8 | 66/M | 0.4 | 0 | M3v | + | − |
| 9 | 32/F | 77.4 | 95 | M3v | −* | +13* |
| 10 | 16/M | 1.9 | 0 | M3 | + | +8 |
| 11 | 16/F | 3.0 | 2 | M3 | ||
| 12 | 19/F | 3.3† | 0† | M3 | + | − |
| 13 | 30/M | 0.4 | 0 | M3v | + | − |
| 14 | 35/F | 17.0 | 9 | M3 | ||
| 15 | 66/F | 63.1 | 59 | M3 | −‡ | − |
| (4.8) | (83) | |||||
| 16 | 19/M | 10.9 | 83 | M3 | + | del(9)(q12q22) |
| (2.5) | (NA) | |||||
| 17 | 21/F | 6.8 | 27 | M3v | +1-153 | − |
| 18 | 48/M | 1.7 | 45 | M3 | + | − |
| 19 | 36/M | 4.1 | 0 | M3 | ||
| 20 | 47/F | 1.8 | 0 | M3 | + | − |
| Case No. . | Age/Sex . | PB . | FAB Class . | Cytogenetics . | ||
|---|---|---|---|---|---|---|
| WBC (109/L) . | Bl + Pros (%) . | t(15;17) Marker . | Other Marker . | |||
| 1 | 63/M | 13.1 | 42 | M3 | + | +8 |
| 2 | 20/M | 7.3 | 66 | M3 | + | − |
| 3 | 68/M | 0.7 | 13 | M3 | + | − |
| 4 | 27/F | 55.2 | 80 | M3v | + | − |
| 5 | 47/M | 2.4 | 42 | M3 | + | del(16)(q11q24) |
| 6 | 29/F | 68.6 | 85 | M3 | + | − |
| 7 | 25/F | 76.0 | 32 | M3v | + | − |
| 8 | 66/M | 0.4 | 0 | M3v | + | − |
| 9 | 32/F | 77.4 | 95 | M3v | −* | +13* |
| 10 | 16/M | 1.9 | 0 | M3 | + | +8 |
| 11 | 16/F | 3.0 | 2 | M3 | ||
| 12 | 19/F | 3.3† | 0† | M3 | + | − |
| 13 | 30/M | 0.4 | 0 | M3v | + | − |
| 14 | 35/F | 17.0 | 9 | M3 | ||
| 15 | 66/F | 63.1 | 59 | M3 | −‡ | − |
| (4.8) | (83) | |||||
| 16 | 19/M | 10.9 | 83 | M3 | + | del(9)(q12q22) |
| (2.5) | (NA) | |||||
| 17 | 21/F | 6.8 | 27 | M3v | +1-153 | − |
| 18 | 48/M | 1.7 | 45 | M3 | + | − |
| 19 | 36/M | 4.1 | 0 | M3 | ||
| 20 | 47/F | 1.8 | 0 | M3 | + | − |
All data are presentation, pretreatment values except for the additional presalvage therapy values listed in parentheses for cases no. 15 and 16. Abbreviations: APL, acute promyelocytic leukemia; PB, peripheral blood; Bl, blasts; Pros, promyelocytes; FAB, French-American-British; WBC, white blood cells; NA, not available.
46,XX(97/100);47,XX,+13(3/100).
No presalvage therapy values available for case no. 12.
Evaluation based on only 8 metaphase figures; all others are based on ≥20 metaphase figures.
t(15;16;17)(q22;p13;q11).